Introduction: To explore the role of balloon tamponade insertion in pregnancies complicated by placenta previa. Evidence acquisition: Medline, Embase and ClinicalTrials.gov databases were searched electronically on October 17. Inclusion criteria were women with placenta previa undergoing, compared to those not undergoing, balloon tamponade insertion at the time of the cesarean section (CS). The outcomes observed were total, intra- and post-operative estimated blood loss (EBL), need for blood transfusion, admission to intensive care unit (ICU), hysterectomy and additional surgical or medical procedures to achieve hemostasis. Results were reported as pooled odd ratios (OR) or mean difference (MD) according to the outcome investigated. Evidence synthesis: Four studies (593 women) were included. Total EBL was significantly lower in women undergoing balloon tamponade insertion during CS compared to controls (MD: -556.3, 95% CI -496 to -617.0, p=0.001). Likewise, women undergoing balloon tamponade insertion had significantly lower intra- (MD: -699.8, 95% CI -766.1 to -633.5, p=0.001) and post-operative (MD: -1162ml (95% CI -1211.1 to -1134.4, p<0.001) compared to women who did undergo such procedure. Furthermore, women undergoing balloon tamponade insertion had a significantly lower risk of requiring additional surgical (OR: 0.16, 95% CI 0.1-0.5, I2: 0%; p=0.001) or medical (OR: 0.02, 95% CI 0.003-0.1, I2: 0; p=0.001) procedures to achieve hemostasis. Conversely, there was no significant difference in either the need for blood transfusion (p= 0.071), admission to ICU (p= 0.459) or need for hysterectomy (p= 0.312) between women undergoing, compared to those not undergoing, balloon tamponade insertion during CS for placenta previa. Conclusions: Elective balloon tamponade insertion at the time of CS for placenta previa seems to be associated with a lower EBL and a reduced risk of additional medical and surgical procedures to control hemostasis. Large and adequately powered randomized controlled trials are needed to validate these results and introduce elective balloon tamponade insertion at the time of CS for placenta previa in clinical practice.
Role of balloon tamponade during cesarean section in women with placenta previa: a systematic review and meta-analysis
Greco, Pantaleo;
2022
Abstract
Introduction: To explore the role of balloon tamponade insertion in pregnancies complicated by placenta previa. Evidence acquisition: Medline, Embase and ClinicalTrials.gov databases were searched electronically on October 17. Inclusion criteria were women with placenta previa undergoing, compared to those not undergoing, balloon tamponade insertion at the time of the cesarean section (CS). The outcomes observed were total, intra- and post-operative estimated blood loss (EBL), need for blood transfusion, admission to intensive care unit (ICU), hysterectomy and additional surgical or medical procedures to achieve hemostasis. Results were reported as pooled odd ratios (OR) or mean difference (MD) according to the outcome investigated. Evidence synthesis: Four studies (593 women) were included. Total EBL was significantly lower in women undergoing balloon tamponade insertion during CS compared to controls (MD: -556.3, 95% CI -496 to -617.0, p=0.001). Likewise, women undergoing balloon tamponade insertion had significantly lower intra- (MD: -699.8, 95% CI -766.1 to -633.5, p=0.001) and post-operative (MD: -1162ml (95% CI -1211.1 to -1134.4, p<0.001) compared to women who did undergo such procedure. Furthermore, women undergoing balloon tamponade insertion had a significantly lower risk of requiring additional surgical (OR: 0.16, 95% CI 0.1-0.5, I2: 0%; p=0.001) or medical (OR: 0.02, 95% CI 0.003-0.1, I2: 0; p=0.001) procedures to achieve hemostasis. Conversely, there was no significant difference in either the need for blood transfusion (p= 0.071), admission to ICU (p= 0.459) or need for hysterectomy (p= 0.312) between women undergoing, compared to those not undergoing, balloon tamponade insertion during CS for placenta previa. Conclusions: Elective balloon tamponade insertion at the time of CS for placenta previa seems to be associated with a lower EBL and a reduced risk of additional medical and surgical procedures to control hemostasis. Large and adequately powered randomized controlled trials are needed to validate these results and introduce elective balloon tamponade insertion at the time of CS for placenta previa in clinical practice.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
